Characterization of a fusion protein of RGD4C and the β-lactamase variant for antibody-directed enzyme prodrug therapy

OncoTargets and Therapy

Volumn 7, Issue , 2014, Pages 535-541

  Zhou, Xiaoliang ^a   Wang, Hao ^a   Shi, Peiji ^a   Meng, Ai Min ^a  

^a INSTITUTE OF RADIATION MEDICINE   (China)

Author keywords

ADEPT; Immunogenicity

Indexed keywords

BETA LACTAMASE; CEPHALOSPORIN; CEPHALOSPORIN PLUS MELPHALAN; HYBRID PROTEIN; MELPHALAN; NITROCEFIN; PEPTIDE; RGD4C BETA LACTAMASE; RGD4C PEPTIDE; UNCLASSIFIED DRUG; VITRONECTIN RECEPTOR;

ANIMAL CELL; ANTIBODY DIRECTED ENZYME PRODRUG THERAPY; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG STABILITY; DRUG TARGETING; HUMAN; HUMAN CELL; HYDROLYSIS; IMMUNOGENICITY; LUNG NON SMALL CELL CANCER; MOUSE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL;

EID: 84898417129     PISSN: 11786930     EISSN: None     Source Type: Journal    
DOI: 10.2147/OTT.S59346     Document Type: Article

References (14)

1. Wang H, Chen K, Cai W, et al. Integrin-targeted imaging and therapy with RGD4C-TNF fusion protein. Mol Cancer Ther. 2008;7(5):1044-1053.
2. Tucker GC. Integrins: molecular targets in cancer therapy. Curr Oncol Rep. 2006;8(2):96-103.
3. Koivunen E, Wang B, Ruoslahti E. Phage libraries displaying cyclic peptides with different ring sizes: ligand specificities of the RGD-directed integrins. Biotechnology (N Y). 1995;13(3):265-270.
4. Kerr DE, Li Z, Siemers NO, Senter PD, Vrudhula VM. Development and activities of a new melphalan prodrug designed for tumor-selective activation. Bioconjug Chem. 1998;9(2):255-259.
5. Goding JW. Conjugation of antibodies with fluorochromes: modifications to the standard methods. J Immunol Methods. 1976;13(3-4):215-226.
6. Wang H, Shi PJ, Wu MF, Li N, Zhou XL, Fan FY. Construction, expression and functional characterization of the β-lactamase with αv integrin ligands. Protein Pept Lett. 2010;17(12):1562-1565.
7. Schellmann N, Deckert PM, Bachran D, Fuchs H, Bachran C. Targeted enzyme prodrug therapies. Mini Rev Med Chem. 2010;10(10):887-904.
8. Bagshawe KD. Targeting: the ADEPT story so far. Curr Drug Targets. 2009;10(2):152-157.
9. Sharma SK, Bagshawe KD, Begent RH. Advances in antibody-directed enzyme prodrug therapy. Curr Opin Investig Drugs. 2005;6(6): 611-615.
10. Mayer A, Francis RJ, Sharma SK, et al. A phase I study of single administration of antibody-directed enzyme prodrug therapy with the recombinant anti-carcinoembryonic antigen antibody-enzyme fusion protein MFECP1 and a bis-iodo phenol mustard prodrug. Clin Cancer Res. 2006;12(21):6509-6516.
11. Abraham S, Guo F, Li LS, et al. Synthesis of the next-generation therapeutic antibodies that combine cell targeting and antibody-catalyzed prodrug activation. Proc Natl Acad Sci U S A. 2007;104(13): 5584-5589.
12. Kaliyaperumal A, Jing S. Immunogenicity assessment of therapeutic proteins and peptides. Curr Pharm Biotechnol. 2009;10(4):352-358.
13. Brinks V, Jiskoot W, Schellekens H. Immunogenicity of therapeutic proteins: the use of animal models. Pharm Res. 2011;28(10): 2379-2385.
14. Chirmule N, Jawa V, Meibohm B. Immunogenicity to therapeutic proteins: impact on PK/PD and efficacy. AAPS J. 2012;14(2): 296-302.